| Acceptance rate | 46% |
|---|---|
| Time to first decision | 6 months* |
| Time to decision with review | 50 days* |
*Approximate number of days
**The days mentioned above are averages and do not indicate exact durations. The process may vary for each article.
ACTA Pharmaceutica Sciencia
2021 , Vol 59 , Num 1
Formulation and In vivo Pharmacodynamics studies of Nanostructured Lipid Carriers for Topical Delivery of Bifonazole
1 M.M College of Pharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana, Ambala, Haryana, India2 Institute of Pharmaceutical Sciences, Kurukshetra University, Kurukshetra-136119, India
3 Department of Pharmaceutical Sciences, Indira Gandhi University, Meerpur, Rewari, Haryana, India, Pharmaceutics, Rewari, India
4 Institute of Pharmaceutical Research, GLA University, Mathura, Uttar Pradesh,, Pharmaceutical Chemistry, Mathura, India
DOI : 10.23893/1307-2080.APS.05902 Viewed : 18189 - Downloaded : 4612 The main objective of the present study was to developed and evaluated the Bifonazole (BFZ) loaded Nanostructured lipid carriers (NLCs) for topical delivery of BFZ. BFZ-NLCs were deve560ted for Particle size, EE, DL and drug release profiles. The invitro release studies show better drug release over 24h as compared to the marketed formulation. Ex-vivo skin permeation and Pharmacodynamic studies indicated that NLCs get effectively reduced the fungal infection. In-vitro antifungal activity study shows that the BFZ-NLCs were more effective in inhibiting the growth of Candida Albicans. Therefore, the study concludes that NLCs showed a continuous release profile and has the prospective for treatment of topical fungal infections. Keywords : Bifonazole, Nanostructured lipid carriers, Topical delivery, Anti-fungal infection, High pressure homogenization